AARD (Aardvark Therapeutics Inc.) Earnings per share for the last four quarters

Aardvark Therapeutics Inc (AARD) is a biopharmaceutical startup developing treatments for obesity and rare genetic metabolic pathologies, which is attracting interest from the market's largest players. Small molecule production has been outsourced to third-party contractors, while the scientific research remains concentrated in California centers. Independence from macroeconomic factors gives the asset defensive qualities. This price chart, serving as the primary valuation tool, confirms these data, with EPS TTM standing at -48.40.
AARD (Aardvark Therapeutics Inc): analytical breakdowns and indicator data

This indicator's dynamics reflect the sensitivity of net income to operating expenses on a per-share basis. The metric measures the rate of change in earnings over the last twelve months, determining the business's capitalization phase. For Aardvark Therapeutics Inc (AARD), which spends on clinical trials without generating revenue, this figure captures increasing losses. By analyzing the annual growth rate of net income per share (TTM), an investor assesses the capital burn rate.